Fertility, Outsourced

Progyny, and the Restructuring of Reproductive Coverage

Fertility care did not suddenly become relevant, nor did it quietly emerge as a fringe offering within modern medicine. Fertility services, including IVF, have been a core component of reproductive care for decades, refined through iterative advances in embryology, hormonal control, and laboratory innovation. Yet insurance coverage has evolved as though this progress never fully occurred, treating fertility as an “optional extension” rather than an integrated domain of care. For many patients, the existence of treatment is not the barrier. The absence of coverage is.

This gap is not incidental. Traditional insurers have long avoided fertility benefits due to their episodic cost structure and the difficulty of modeling utilization across a population. Unlike hypertension or diabetes, fertility does not distribute evenly, nor does it behave predictably across time. Faced with that variability, insurers did not refine their models. They excluded the category.

The consequence is a system that appears coherent from a distance but fragments under scrutiny. Two patients with identical diagnoses may encounter entirely different financial realities depending on their employer’s benefit design. Clinical indication becomes secondary to coverage architecture, and access begins to feel less like a right and more like a negotiated privilege.

Markets, however, do not leave persistent gaps untouched. When a service is both necessary and systematically excluded, a secondary structure emerges to bridge the divide. That structure is not born from novelty, but from absence. Progyny exists within that absence, and its success reflects the durability of the gap that created it.

The Business of Filling the Void

Without a doubt, Progyny has built its model with precision. It contracts directly with employers, designs fertility-specific benefits, and manages access through a curated network of providers. It does not function as an insurer, nor does it deliver care itself. Instead, it orchestrates the interaction between employer demand and clinical supply, creating a pathway where none previously existed.

The elegance of the model lies in what it avoids. Progyny does not assume underwriting risk, nor does it carry the operational burden of running clinics. It occupies an intermediary position, extracting value from coordination rather than ownership. In doing so, it converts a fragmented and emotionally charged domain into something that appears structured, predictable, and administratively manageable.

It is, in other words, the definition of a middleman.

Financially, the approach has proven highly effective. With projected revenues exceeding $1.3 billion in 2026, Progyny has demonstrated that brokering access to excluded care is not only viable, but scalable. Employers, faced with growing demand for fertility benefits, are willing to pay for a solution that their insurers have declined to provide. Progyny has positioned itself as that solution, embedding into benefits packages as if it were always meant to be there.

But the underlying logic is difficult to ignore. If fertility care were broadly covered within traditional insurance models, the need for Progyny would contract sharply. Its success is therefore not independent of the system, but contingent upon its limitations. It is, in a very real sense, a broker of absence, profitable because something foundational remains unaddressed.

A Company Without a Governor

To further muddy the waters, Progyny operates within healthcare, but not fully inside its traditional regulatory boundaries. It is not an insurer and therefore does not fall under the same oversight structures that govern payer behavior. Its benefit designs, clinical pathways, and network decisions are largely defined internally, shaped by company policy rather than external mandate.

This autonomy creates both flexibility and opacity. On one hand, Progyny can iterate quickly, refining its model without the friction of regulatory constraint. On the other, the absence of standardized oversight introduces variability that is more difficult to assess from the outside. The system functions, but the mechanisms by which it functions are not always transparent.

Even at the level of consumer-facing accountability, the structure is relatively light. Progyny is not accredited by the Better Business Bureau, and publicly available reviews suggest inconsistency in patient experience. These signals are imperfect, but they point toward a broader truth: external validation is limited, and quality is largely defined from within.

In most areas of healthcare, oversight is layered - regulators, accrediting bodies, and payers each contributing to a system of checks and balances. Here, those layers are thinner. The company sets its own parameters and operates within them, a structure that grants efficiency while raising questions about accountability at scale.

The Emerging Pattern

Progyny is often discussed as though it were unique company, but this is not true. It is better understood as an early adaptor of a broader pattern. When traditional systems decline to cover a category of care, secondary companies emerge to occupy the space left behind. These companies do not disrupt the system in the conventional sense. They adapt to its omissions.

Fertility is simply one expression of this dynamic. Similar conditions exist in other areas of medicine - rare diseases, infusion therapies, advanced biologics - where costs are high, pathways are complex, and insurers remain cautious in their engagement. Each of these domains presents an opportunity for a Progyny-like model to develop, tailored to the specific contours of the gap.

Over time, these secondary structures begin to accumulate. What starts as a series of targeted solutions evolves into a parallel layer of care, operating alongside traditional insurance but governed by different rules. Patients move between these layers, often without recognizing the boundaries that separate them.

The Future of Coverage Design

If this trajectory continues, the architecture of insurance itself may begin to shift as well. Rather than functioning as a comprehensive model, coverage may evolve into a baseline framework - broad in scope but intentionally limited in depth. Around that baseline, additional layers would be added, selected based on need, preference, and financial tolerance.

The analogy is not subtle. This is how complexity is managed in other industries, where a standard product is augmented through optional features. In healthcare, this would translate into a system where baseline, life-saving foundational care is assumed, but specialized services are appended through separate mechanisms. Fertility today, other domains tomorrow.

In such a model, companies like Progyny are not peripheral. They become integral components, each responsible for a defined segment of care that the base system does not include. Their presence would no longer signal a gap, but a design choice.

And as these layers mature, the incentive to expand the underlying system diminishes. What began as a workaround settles into permanence, and the boundary between core care and optional coverage becomes increasingly difficult to define.

© 2026 Corey R. Babb, DO, FACOOG, IF, MSCP. All rights reserved